Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Overview

Información sobre este estudio

The purpose of this study is to to determine the effect to overall survival (OS) by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

1. Histological or biopsy proven adenocarcinoma of the pancreas. Cytology is acceptable
if histology cannot be obtained.

2. Newly diagnosed non-metastatic PC judged by tumor board to be feasible for SBRT

3. Completed at least 6 weeks of chemotherapy consisting of FOLFIRINOX, mFOLFIRINOX, or a
gemcitabine-based doublet regimen prior to start of SBRT

4. Remain non-metastatic as confirmed by a CT scan at screening.

5. Female or male subjects ≥ 18 years of age

6. ECOG performance status of 0-2

7. Adequate end-organ function

Exclusion Criteria:

1. Subjects with documented metastatic disease

2. First-line chemotherapy other than FOLFIRINOX, mFOLFIRINOX, and/or a gemcitabine-based
doublet regimen

3. Prior abdominal RT with substantial overlap in radiation fields

4. Subjects not recovered/controlled from treatment-related toxicities

5. Uncontrolled malignancy other than PC

6. Uncontrolled gastric or duodenal ulcer disease within 30 days of dosing

7. Visible invasion of bulky tumor into the lumen of the bowel or stomach on endoscopy

Eligibility last updated 5/9/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Kenneth Merrell, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20528748

Mayo Clinic Footer